House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Psychiatry

Attention deficit hyperactivity disorder: diagnosis and management

NICE · 2019 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG87 recommends specialist ADHD assessment across settings, a shared treatment plan with environmental support, and age-specific medication choices when impairment persists. Medication requires baseline cardiovascular and mental-health assessment, individualized titration and ongoing growth, cardiovascular and adverse-effect monitoring.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Diagnose clinically across settings and refer according to impairment

  • ADHD diagnosis requires a trained specialist’s clinical and psychosocial assessment, developmental and psychiatric history, observer reports and mental-state assessment. Do not diagnose from rating scales or observation alone; symptoms should meet diagnostic criteria, cause at least moderate impairment and occur in at least 2 important settings. [1]
  • In children with possible ADHD, assess severity and impact across settings. Refer directly for severe impairment; persistent moderate impairment after initial support also warrants specialist assessment. Primary care should not make the initial diagnosis or start medication in children or young people. [1]
  • Refer previously undiagnosed adults when typical symptoms began in childhood, persisted through life, are not explained by another psychiatric diagnosis and cause moderate or severe impairment. Coexisting psychiatric conditions do not themselves exclude ADHD; recognize that girls and women may be under-recognized. [1]
  • Build a holistic shared plan addressing psychological, behavioural, educational or occupational needs. Discuss treatment benefits, harms and preferences, and arrange environmental modifications and appropriate family or educational support with consent. [1]

Use parent support and environmental changes before escalation

  • For children under 5, offer ADHD-focused group parent training first. If significant impairment persists across settings after training and environmental changes, seek specialist early-childhood ADHD advice. Do not offer medication without a second specialist opinion from such a service. [1]
  • For children aged 5 and over and young people, offer medication only if significant impairment persists in at least one domain despite reviewed environmental changes, ADHD information has been discussed with the family and a baseline assessment is complete. Offer parent support; coexisting oppositional or conduct symptoms warrant parent training. [1]
  • For adults, offer medication if significant impairment persists after environmental changes. Consider ADHD-focused psychological treatment for informed refusal, adherence difficulty, ineffective or intolerable medication, or residual impairment despite benefit; provide structured support and regular follow-up, potentially including CBT. [1]

Confirm need and evaluate cardiovascular and misuse risk

  • Medication should be initiated by a clinician trained in ADHD management. Before treatment, confirm diagnosis and need, review comorbidity, substance misuse or diversion risk, medical history and medicines, and measure height, weight, pulse and blood pressure with a cardiovascular assessment. [1]
  • A routine ECG is unnecessary before stimulants, atomoxetine or guanfacine unless cardiac warning features or another medicine increasing cardiac risk are present. Refer for cardiology opinion before ADHD medication with congenital heart disease or previous cardiac surgery; sudden death suggesting cardiac disease in a first-degree relative under 40; exertional breathlessness; exertional or fright/noise-related fainting; rapid regular abrupt-onset/offset palpitations; cardiac-type chest pain; heart-failure signs; a murmur; or adult hypertension. [1]
  • Before starting ADHD medication, refer children and young people whose blood pressure is consistently above the 95th centile for age and height to a paediatric hypertension specialist. [1]

Follow separate child and adult medication choices

  • For children aged 5 and over and young people, offer methylphenidate first. Consider lisdexamfetamine after an adequate-dose 6-week methylphenidate trial gives insufficient benefit. If lisdexamfetamine helps but its longer duration is intolerable, consider dexamfetamine. [1]
  • For children aged 5 and over and young people, offer atomoxetine or guanfacine if methylphenidate or lisdexamfetamine is intolerable, or symptoms persist after separate adequate-dose 6-week trials of both, with alternative preparations considered. [1]
  • For adults, offer lisdexamfetamine or methylphenidate first and consider switching to the other after an adequate-dose 6-week trial with insufficient benefit. Consider dexamfetamine if lisdexamfetamine works but its longer effect profile cannot be tolerated. [1]
  • Offer atomoxetine to adults if either first-line stimulant is intolerable or separate adequate-dose 6-week trials of both fail after considering alternative preparations. Obtain a second opinion or tertiary referral when symptoms are unresponsive to one or more stimulants and one non-stimulant. [1]
  • Anxiety, tic disorder or autism does not change the offered medication choices, but titrate more slowly and monitor more often with neurodevelopmental, mental-health or relevant physical comorbidity. Stop ADHD medication during an acute psychotic or manic episode and reconsider it individually after resolution. [1]
  • Record symptoms, impairment and adverse effects at baseline and each titration change, with regular specialist review. Optimize benefit against tolerability; consider once-daily modified-release preparations for practical and adherence reasons, and avoid easily misused preparations when diversion risk exists. [1]

Track growth, cardiovascular effects and continuing benefit

  • On medication, measure child and adolescent height every 6 months and weight every 3 months at age 10 or younger. Above age 10, check weight at 3 and 6 months after starting, then every 6 months; adults need 6-monthly weight checks. Plot children’s growth and review concerns sooner. [1]
  • For concerning weight loss, consider food timing, additional meals when stimulant effects fade, dietetic advice, nutritious calorie-dense food, a planned treatment break or medication change. If childhood height gain is significantly affected, consider a planned school-holiday break for catch-up growth. [1]
  • Check heart rate and blood pressure before and after each dose change and every 6 months. Routine blood tests or ECGs are unnecessary without a clinical indication. Sustained resting heart rate above 120, arrhythmia, or systolic pressure above the 95th percentile or a clinically significant increase on 2 occasions requires dose reduction and referral. [1]
  • Reduce or switch guanfacine for persistent orthostatic hypotension or fainting. Review new or worsening seizures and stop a potentially contributing medicine while investigating; monitor sleep and behavioural changes and adjust treatment or review diagnosis when needed. [1]
  • Support adherence with clear instructions, reminders and routines; parents should oversee medication for children and young people. After titration and stabilization, use shared-care prescribing and monitoring arrangements, with follow-up according to severity even when medication is not used. [1]
  • Review medication at least annually with an ADHD-trained clinician, discussing benefits, adverse effects, continuing need, functioning, missed doses and patient preferences. Consider planned dose reduction or stopping trials when the overall balance supports it and document reasons for continuing. [1]

Limitations and use

  • This summary does not supply dose schedules or all formulation-specific contraindications, licensing restrictions or interactions. The source notes off-label use for some age groups and indications, including several medicines at age five; consult current product and local prescribing guidance. Specialist and shared-care arrangements described here reflect the NICE service setting.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Attention deficit hyperactivity disorder: diagnosis and management

    Selected recommendation material consulted

Clinical guideline

Publication details

Issuing organisation
NICE
First published
14 March 2018
Publisher’s latest update
13 September 2019
Resource type
Clinical guideline · House clinical summary
Source setting
United Kingdom

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Diagnose clinically across settings and refer according to impairment
  • Use parent support and environmental changes before escalation
  • Confirm need and evaluate cardiovascular and misuse risk
  • Follow separate child and adult medication choices
  • Track growth, cardiovascular effects and continuing benefit
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House